Navigation Links
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
Date:9/25/2007

PINE BROOK, N.J., Sept. 25 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced it has been awarded a contract for $12 million for advanced development of Anthim(TM), the company's late-stage anthrax therapeutic. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, under Contract No. HHSN272200700035C. To date, Elusys has received more than $32 million from NIAID/BARDA and the Department of Defense in support of Anthim and the company's Heteropolymer Antibody(TM) technology.

Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented on the award, "Elusys is encouraged by the continued support from the U.S. Government and we look forward to extending our collaboration with NIAID/BARDA. We are confident that Elusys has developed a highly effective and valuable anthrax therapeutic for procurement under Project BioShield for addition to the U.S. Government's Strategic National Stockpile."

Dr. Posillico continued, "Inhalation of anthrax spores rapidly leads to death if patients are not treated immediately with specific antibiotics. Typically, victims of inhalation anthrax experience only vague symptoms until it is too late, when they are in toxemia, leaving antibiotics largely ineffective. Anthrax vaccines are also ineffective unless victims are immunized well in advance of exposure. Anthim represents a 'just in time anthrax therapeutic,' that in relevant models has demonstrated complete protection against an anthrax spore challenge with a single prophylactic dose, and has shown significant protection when administered up to two days after a lethal spore challenge, with or without an antibiotic."

Anthim(TM) Background

Anthim is high affinity monoclonal antibody that targets the protective antigen component of anthrax infection, blocking the bacteria's ability to form deadly toxins. It is being developed for prophylaxis and post-exposure treatment of inhalation anthrax. Anthim has been granted Fast Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs.

About Elusys' Heteropolymer Antibody(TM) Technology

HP Antibodies represent a new approach for the treatment of antibiotic resistant infections distinct from traditional therapies. HP Antibodies utilize natural immune system mechanisms to clear pathogens and provide a means to develop novel drug candidates targeted against bacterial, viral and fungal infections. By targeting a unique immune receptor, HP Antibodies enhance a natural clearance mechanism and direct the rapid removal of pathogens from the circulation to tissue macrophages. Elusys is currently working on novel approaches to the treatment of Staphylococcus and Candida infections using HP antibodies.

About Elusys

Elusys is a privately held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life- threatening infectious disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
9. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended ... adolescents aged 13 years, and above. Effective immediately, the PrePex ... and adolescent males in the 14 priority countries in Southern ... first male circumcision device to receive WHO Prequalification on 31 ... said: " The expanded use of PrePex ...
(Date:5/23/2016)... -- Gamida Cell, a leader in cellular ... orphan genetic diseases, announced today it has been awarded ... Israel Innovation Authority (formerly the Office of the Chief ... The mission of the Israel Innovation Authority is to ... and technology, while stimulating economic growth. The ...
(Date:5/22/2016)... DUBLIN , May 23, 2016 ... to develop its anti-fibrotic and anti-inflammatory compound DS102 ... well as in non-alcoholic steatohepatitis (NASH) patients. ... is significantly sequestered in lung tissue and has ... tissue after oral administration. The Company will publish ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and raise awareness of ... have access to a toilet, even when they’re on their periods. , WaterAid asked over ... results help shine a light on the awkwardness that women face while menstruating, even in ...
(Date:5/24/2016)... MA (PRWEB) , ... May 24, 2016 , ... ... Harvard Medical School, today announced a licensing relationship that will deliver a new ... This relationship will put the medical knowledge and expertise of Harvard Medical ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... of safety signs and safety labels , has been featured ... Symbols: Laser Labels.” , The eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, ...
(Date:5/24/2016)... Conn. (PRWEB) , ... May 24, 2016 , ... After ... . He spent the next decade in hospitals, on medication, living on Social Security ... Look at the Illness and How I Beat It!” (published by Balboa Press), Alexander ...
(Date:5/24/2016)... ... May 24, 2016 , ... Design Concepts , ... Centro del Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was designed ... something special for this often overlooked neighborhood. Located at 609 E. 6th Street, ...
Breaking Medicine News(10 mins):